166 related articles for article (PubMed ID: 35171984)
1. Use of Human Leukocyte Antigen (HLA)-Incompatible Platelet Units in HLA Platelet-Refractory Patients With Limited Number of or Low-Level HLA Donor-Specific Antibodies Results in Permissive Transfusions.
Sullivan JC; Peña JR
Arch Pathol Lab Med; 2022 Oct; 146(10):1243-1251. PubMed ID: 35171984
[TBL] [Abstract][Full Text] [Related]
2. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
Karafin MS; Schumacher C; Zhang J; Simpson P; Johnson ST; Pierce KL
Transfusion; 2021 Aug; 61(8):2307-2316. PubMed ID: 34075590
[TBL] [Abstract][Full Text] [Related]
3. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
[TBL] [Abstract][Full Text] [Related]
4. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience.
Karlström C; Linjama T; Edgren G; Lauronen J; Wikman A; Höglund P
Transfusion; 2019 Mar; 59(3):945-952. PubMed ID: 30575964
[TBL] [Abstract][Full Text] [Related]
5. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-HLA antibodies for stem cells engraftment in haploidentical transplantation.
Zhang R; He Y; Yang D; Jiang E; Ma Q; Pang A; Zhai W; Wei J; Feng S; Han M
J Clin Lab Anal; 2020 Jul; 34(7):e23261. PubMed ID: 32112480
[TBL] [Abstract][Full Text] [Related]
8. Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.
Elhence P; Chaudhary RK; Nityanand S
Blood Transfus; 2014 Apr; 12(2):180-6. PubMed ID: 24333069
[TBL] [Abstract][Full Text] [Related]
9. Use of in vitro assays in selection of compatible platelet donors.
Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with Hematologic Disorders.
Neanaey WA; Deghady AA; Nafea DA; Fahmy NM; Gouda AM
Oman Med J; 2022 Jul; 37(4):e402. PubMed ID: 35915764
[TBL] [Abstract][Full Text] [Related]
11. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.
Saito S; Ota S; Seshimo H; Yamazaki Y; Nomura S; Ito T; Miki J; Ota M; Fukushima H; Maeda H
Transfusion; 2002 Mar; 42(3):302-8. PubMed ID: 11961234
[TBL] [Abstract][Full Text] [Related]
12. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
14. Effect of HLA Bw4/Bw6 compatibility on platelet transfusion responses of refractory thrombocytopenic patients.
McElligott MC; Menitove JE; Duquesnoy RJ; Hunter JB; Aster RH
Blood; 1982 May; 59(5):971-5. PubMed ID: 6951616
[TBL] [Abstract][Full Text] [Related]
15. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
16. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
17. Platelet donor selection for HLA-immunised patients; the impact of donor-specific HLA antibody levels.
Linjama T; Niittyvuopio R; Tuimala J; Pyörälä M; Rintala H; Rimpiläinen J; Kauppila M; Peräsaari J; Juvonen E
Transfus Med; 2017 Oct; 27 Suppl 5():375-383. PubMed ID: 28382715
[TBL] [Abstract][Full Text] [Related]
18. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion.
Rioux-Massé B; Cohn C; Lindgren B; Pulkrabek S; McCullough J
Transfusion; 2014 Dec; 54(12):3080-7. PubMed ID: 24916382
[TBL] [Abstract][Full Text] [Related]
19. Management of the Platelet Refractory Patient.
Forest SK; Hod EA
Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
[TBL] [Abstract][Full Text] [Related]
20. ABO and platelet transfusion revisited.
Heal JM; Rowe JM; Blumberg N
Ann Hematol; 1993 Jun; 66(6):309-14. PubMed ID: 8318561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
